In advanced melanoma with acquired immunotherapy resistance (such as anti-PD-1 and anti-CTLA-4 mAbs), loss-of function (LOF) mutations are very frequent, especially in such important genes as JAK1/2, IRF1, and IFNGRI1/2 [1,28]. The gene discussed is PDCD1; the disease is melanoma.